2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

Steffel, Jan, Collins, Ronan, Antz, Matthias, Cornu, Pieter, Desteghe, Lien, Haeusler, Karl Georg, Oldgren, Jonas, Reinecke, Holger, Roldan-Schilling, Vanessa, Rowell, Nigel, Sinnaeve, Peter, Vanassche, Thomas, Potpara, Tatjana, Camm, A John, Heidbüchel, Hein, External reviewers, Lip, Gregory Y H, Deneke, Thomas, Dagres, Nikolaos, Boriani, Giuseppe, Chao, Tze-Fan, Choi, Eue-Keun, Hills, Mellanie True, Santos, Itamar de Souza, Lane, Deirdre A, Atar, Dan, Joung, Boyoung, Cole, Oana Maria, Field, Mark·2021·EP Europace
DOI 10.1093/europace/euab065

Cites (558)

Items 201–400 of 556

  1. Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
    Jeanne Mendell, Hamim Zahir, Nobuko Matsushima, Robert Joseph Noveck, Frank Lee, Shuquan Chen, George Zhang, Minggao Shi · 2013 · American Journal of Cardiovascular Drugs
  2. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries
    Benjamin Adam Steinberg, Haiyan Gao, Peter Shrader, Karen Pieper, Laine Elliott Thomas, A. John Camm, Michael D. Ezekowitz, Gregg C. Fonarow, Bernard John Gersh, Samuel Zachary Goldhaber et al. · 2017 · American Heart Journal
  3. European Stroke Organisation guidelines for the management of post-stroke seizures and epilepsy
    Martin Holtkamp, Ettore Beghi, Felix Benninger, Reetta K. Kälviäinen, Rodrigo Rocamora, Hanne Christensen · 2017 · European Stroke Journal
  4. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation
    Tze‐Fan Chao, Chia‐Jen Liu, Yenn‐Jiang Lin, Shih‐Lin Chang, Li‐Wei Lo, Yu‐Feng Hu, Ta‐Chuan Tuan, Jo‐Nan Liao, Fa‐Po Chung, Tzeng‐Ji Chen et al. · 2018 · Circulation
  5. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
    Peter L. Gross, Bruce C. Ritchie, Susan Nahirniak, Yulia Lin, Lani Lieberman, Marc Carrier, Mark Andrew Crowther, Indy Ghosh, Alejandro Lazo‐Langner, Michelle Zondag et al. · 2018 · Thrombosis and Haemostasis
  6. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding
    Ray, Wayne A., Chung, Cecilia P., Murray, Katherine T., Smalley, Walter E., Daugherty, James R., Dupont, William D., Stein, C. Michael · 2018 · JAMA
  7. In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
    Mark Jean Gnoth, Ulf Buetehorn, Uwe Muenster, Thomas Schwarz, Steffen Sandmann · 2011 · Journal of Pharmacology and Experimental Therapeutics
  8. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice
    Gregory Y.H. Lip, Hans‐Christoph Diener, Martina Brueckmann, Joanne van Ryn, Andreas Clemens, Menno Volkert Huisman · 2012 · Thrombosis and Haemostasis
  9. Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban
    Graeme J. Hankey, Susanna R. Stevens, Jonathan Paul Piccini, Yuliya V. Lokhnygina, Kenneth W. Mahaffey, Jonathan L. Halperin, Manesh R. Patel, GÜNTER E. BREITHARDT, Daniel E. Singer, Richard Clinton Becker et al. · 2014 · Stroke
  10. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme
    Stephan Rietbrock, Emma L. Heeley, Jonathan Plumb, Tjeerd Pieter van Staa · 2008 · American Heart Journal
  11. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline
    Catharina J.M. Klijn, Maurizio Paciaroni, Eivind Berge, Eleni Korompoki, Janika Kõrv, Avtar Lal, Jukka Putaala A, David John Werring · 2019 · European Stroke Journal
  12. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide
    Christian Chatelain, Bernard Châtelain, Jonathan Douxfils, Jean‐Michel Dogné, François Mullier · 2013 · Thrombosis and Haemostasis
  13. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review
    Theodore Earl Warkentin, Menaka Pai, Lori‐Ann Linkins · 2017 · Blood
  14. New Oral Anticoagulants and the Cancer Patient
    Nicholas James Short, Jean M. Connors · 2013 · The Oncologist
  15. Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
    Benjamin Adam Steinberg, Peter Shrader, Karen S. Pieper, Laine Elliott Thomas, Larry A. Allen, Jack Ansell, Paul S. Chan, Michael D. Ezekowitz, Gregg C. Fonarow, James V. Freeman et al. · 2018 · Journal of the American Heart Association
  16. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding
    Theodore Earl Warkentin, Peter J. Margetts, Stuart J. Connolly, Andre L. Lamy, Chris Ricci, John W. Eikelboom · 2012 · Blood
  17. Poor Prognosis in Warfarin-Associated Intracranial Hemorrhage Despite Anticoagulation Reversal
    Dar D Dowlatshahi, Kenneth Butcher, Negar Asdaghi, Susan Nahirniak, Manya L. Bernbaum, Antonio Giulivi, Jason K. Wasserman, Man-Chiu Poon, Shelagh B. Coutts · 2012 · Stroke
  18. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation
    Chern‐En Chiang, Ken Okumura, Shu Zhang, Tze‐Fan Chao, Chung‐Wah Siu, Toon Wei Lim, Anil Saxena, Yoshihide Takahashi, Wee Siong Teo · 2017 · Journal of Arrhythmia
  19. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
    Gerhard Hindricks, Tatjana Potpara, Nikolaos Dagres, Elena Arbelo, Jeroen Joost Bax, Carina Blomström‐Lundqvist, Giuseppe Boriani, Manuel Castellà, Gheorghe‐Andrei Dan, Polychronis Dilaveris et al. · 2021 · Russian Journal of Cardiology
  20. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients
    Yu‐Feng Hu, Chia-Jen Liu, Peter Mu‐Hsin Chang, Hsuan-Ming Tsao, Yenn‐Jiang Lin, Shih‐Lin Chang, Li‐Wei Lo, Ta‐Chuan Tuan, Cheng Hung Li, Tze‐Fan Chao et al. · 2012 · International Journal of Cardiology
  21. Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers
    Marcel M Levi, Kenneth Todd Moore, C.F. Castillejos, Dagmar Kubitza, Scott D. Berkowitz, Samuel Zachary Goldhaber, Maikel Raghoebar, M.R. Patel, Jeffrey Ian Weitz, Jerrold H. Levy · 2014 · Journal of Thrombosis and Haemostasis
  22. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
    Breithardt, Günter, Baumgartner, Helmut, Berkowitz, Scott D., Hellkamp, Anne S., Piccini, Jonathan P., Stevens, Susanna R., Lokhnygina, Yuliya, Patel, Manesh R., Halperin, Jonathan L., Singer, Daniel E. et al. · 2014 · European Heart Journal
  23. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS)
    Christian Sticherling, Francisco R. Marín, David H. Birnie, Giuseppe Boriani, Hugh G Calkins, Gheorghe‐Andrei Dan, Michele Massimo Gulizia, Sigrun Halvorsen, Gerhard Hindricks, Karl‐Heinz Kück et al. · 2015 · EP Europace
  24. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model
    Ingo Pragst, Stefanie Zeitler, Baerbel Doerr, Franz Kaspereit, Eva Herzog, Gerhard Dickneite, Joanne van Ryn · 2012 · Journal of Thrombosis and Haemostasis
  25. Atrial fibrillation as a risk factor for cognitive decline and dementia
    Singh-Manoux, Archana, Fayosse, Aurore, Sabia, Séverine, Canonico, Marianne, Bobak, Martin, Elbaz, Alexis, Kivimäki, Mika, Dugravot, Aline · 2017 · European Heart Journal
  26. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation
    Surbhi Shah, Faye L. Norby, Yvonne H. Datta, Pamela L. Lutsey, Richard F. MacLehose, Lin Y. Chen, Álvaro Alonso · 2018 · Blood Advances
  27. Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11–13 November 2018
    Niaz Ahmed, Heinrich J. Audebert, Guillaume Turc, Charlotte Cordonnier, Hanne Christensen, Simona Sacco, Else Charlotte Sandset, George Ntaios, Andreas Charidimou, Danilo Toni et al. · 2019 · European Stroke Journal
  28. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF)
    Gregory Y.H. Lip, Christoph Hammerstingl, Francisco R. Marín, Riccardo Cappato, Isabelle Ling Meng, Bodo Kirsch, Martin van Eickels, Ariel A. Cohen · 2016 · American Heart Journal
  29. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Dialysis
    Toshiki Kuno, Hisato Takagi, Tomo Ando, Takehiro Sugiyama, Satoshi Miyashita, Nelson Valentin, Yuichi J. Shimada, Masaki Kodaira, Yohei Numasawa, Αlexandros Briasoulis et al. · 2020 · Journal of the American College of Cardiology
  30. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease
    John W. Stanifer, Sean D. Pokorney, Glenn Matthew Chertow, Stefan Hans Hohnloser, DANIEL M. WOJDYLA, Samira J. Merali, Wonkyung Byon, Ziad Hijazi, Renato D. Lópes, John Hunter Alexander et al. · 2020 · Circulation
  31. Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting: Is There Any Benefit? A Systematic Review and Meta-Analysis
    Salil Vasudeo Deo, Shannon M. Dunlay, Ishan K. Shah, Salah E. Altarabsheh, Patricia J. Erwin, Barry A. Boilson, Soon J. Park, Lyle D. Joyce · 2013 · Journal of Cardiac Surgery
  32. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial
    Jonathan Paul Piccini, J. Garg, Manesh R. Patel, Yuliya V. Lokhnygina, Shaun G. Goodman, Richard Clinton Becker, Scott D. Berkowitz, Guenter Breithardt, W. Hacke, Jonathan L. Halperin et al. · 2014 · European Heart Journal
  33. Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial
    Ka Sing Wong, Dai Yi Hu, Abraham Oomman, Ru‐San Tan, Manesh R. Patel, Daniel E. Singer, GÜNTER E. BREITHARDT, Kenneth W. Mahaffey, Richard Clinton Becker, Robert M. Califf et al. · 2014 · Stroke
  34. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures
    David A. Garcia, John Hunter Alexander, Lars C. Wallentin, DANIEL M. WOJDYLA, Laine Elliott Thomas, Michael Hanna, Sana M. Al‐Khatib, Paul Dorian, Jack Ansell, Patrick Commerford et al. · 2014 · Blood
  35. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
    Michael D. Ezekowitz, Charles V. Pollack, Jonathan L. Halperin, Richard D. England, Sandra VanPelt Nguyen, Judith Spahr, Maria Sudworth, Nilo B. Cater, Andrei Breazna, Jonas Oldgren et al. · 2018 · European Heart Journal
  36. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling
    Jan Steffel, Robert Patrick Giugliano, Eugene Braunwald, Sabina A. Murphy, Michele F. Mercuri, Youngsook Choi, Philip E. Aylward, Harvey Douglas White, José Luis Zamorano, Elliott Marshall Antman et al. · 2016 · Journal of the American College of Cardiology
  37. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial
    Chiara Melloni, Allison M. Dunning, Christopher Bull Granger, Laine Elliott Thomas, Michel Georges Khouri, David A. Garcia, Elaine M. Hylek, Michael Hanna, Lars C. Wallentin, Bernard John Gersh et al. · 2017 · The American Journal of Medicine
  38. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
    Stefan Hans Hohnloser, A. John Camm, Riccardo Cappato, Hans‐Christoph Diener, Hein Heidbüchel, Lluı́s Mont, Carlos Arturo Morillo, Khalid Abozguia, Massimo Grimaldi, Heiko Rauer et al. · 2019 · European Heart Journal
  39. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial
    Paul Moayyedi, John W. Eikelboom, Jackie Bosch, Stuart J. Connolly, Leanne Dyal, Olga Shestakovska, Darryl P. Leong, Sonia Savitri Anand, Stefan Störk, Kelley R. Branch et al. · 2019 · Gastroenterology
  40. Racial Differences in Atrial Fibrillation-Related Cardiovascular Disease and Mortality
    Jared W. Magnani, Faye L. Norby, Sunil Kumar Agarwal, Elsayed Z. Soliman, Lin Y. Chen, Laura R. Loehr, Álvaro Alonso · 2016 · JAMA Cardiology
  41. The Development and Validation of a Brief Performance-Based Fall Risk Assessment Tool for Use in Primary Care
    Anne Tiedemann, Stephen R. Lord, Catherine Sherrington · 2010 · The Journals of Gerontology Series A
  42. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
    Michael D. Ezekowitz, Rangadham Nagarakanti, Herbert Noack, Martina Brueckmann, Claire Litherland, Mark Jacobs, Andreas Clemens, Paul A. Reilly, Stuart J. Connolly, Salim Yusuf et al. · 2016 · Circulation
  43. Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation
    Mohamed Bassiouny, Walid I. Saliba, John Rickard, Mingyuan Shao, Albert Sey, Mariam Diab, David O. Martin, Ayman Ali Hussein, Maurice Khoury, Bernard Abi‐Saleh et al. · 2013 · Circulation Arrhythmia and Electrophysiology
  44. Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
    Shinya Goto, Jun Zhu, Lisheng Liu, Byung‐Hee Oh, DANIEL M. WOJDYLA, Philip E. Aylward, Maria Cecilia Bahit, Bernard John Gersh, Michael Hanna, John David Horowitz et al. · 2014 · American Heart Journal
  45. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study
    Friberg, Leif, Benson, Lina, Lip, Gregory Y.H. · 2015 · European Heart Journal
  46. Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation
    John J.V. McMurray, Justin Adrian Ezekowitz, Basil S. Lewis, Bernard John Gersh, Sean van Diepen, John V. Amerena, Jozef Bartúnek, Patrick Commerford, Byung‐Hee Oh, Veli‐Pekka Harjola et al. · 2013 · Circulation Heart Failure
  47. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor X a inhibitor
    Charles E. Frost, Wonkyung Byon, Yan Jun Song, Jessie J.J. Wang, Alan E. Schuster, Rebecca A. Boyd, Donglu Zhang, Zhigang Yu, Clapton S. Dias, Andrew Shenker et al. · 2014 · British Journal of Clinical Pharmacology
  48. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study
    Di Biase, Luigi, Lakkireddy, Dhanujaya, Trivedi, Chintan, Deneke, Thomas, Martinek, Martin, Mohanty, Sanghamitra, Mohanty, Prasant, Prakash, Sameer, Bai, Rong, Reddy, Madhu et al. · 2015 · Heart Rhythm
  49. Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
    Dagmar Kubitza, Michael Becka, Wolfgang Mueck, Michael Zuehlsdorf · 2006 · British Journal of Clinical Pharmacology
  50. Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries
    Harriette G.C. Van Spall, Lars C. Wallentin, Salim Yusuf, John W. Eikelboom, Robby Nieuwlaat, Sean Yang, Conrad Kabali, Paul A. Reilly, Michael D. Ezekowitz, Stuart J. Connolly · 2012 · Circulation
  51. Assays for Measuring Rivaroxaban: Their Suitability and Limitations
    Edelgard Lindhoff‐Last, Meyer Michel Samama, Thomas L. Ortel, Jeffrey Ian Weitz, Theodore Erich Spiro · 2010 · Therapeutic Drug Monitoring
  52. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial
    Christina L. Fanola, Christian Thomas Ruff, Sabina A. Murphy, James Jin, Anil Duggal, Noe A. Babilonia, Piyamitr Sritara, Michele F. Mercuri, Pieter Willem Kamphuisen, Elliott Marshall Antman et al. · 2018 · Journal of the American Heart Association
  53. Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis
    Kuo‐Li Pan, Daniel E. Singer, Bruce Ovbiagele, Yi‐Ling Wu, Mohamed Ahmed, Meng Lee · 2017 · Journal of the American Heart Association
  54. Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement
    Julia Seeger, Birgid Gonska, Christoph Rodewald, Wolfgang Rottbauer, Jochen Wöhrle · 2017 · JACC: Cardiovascular Interventions
  55. Dose-Finding Study of Rivaroxaban in Hemodialysis Patients
    An S. De Vriese, Rogier Caluwé, Els Bailleul, Dirk De Bacquer, Daniëlle Borrey, Bruno Van Vlem, Stefaan J. Vandecasteele, Jan Emmerechts · 2015 · American Journal of Kidney Diseases
  56. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study
    Anne Godiér, Anne-Sophie Dincq, Anne‐Céline Martin, Adrian Radu, Isabelle Leblanc, Marion Antona, Marc Vasse, Jean‐Louis Golmard, François Mullier, Isabelle Gouin‐Thibault · 2017 · European Heart Journal
  57. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
    Jeanne Mendell, Helen Kastrissios, MICHELLE L. GREEN, Timothy J. Carrothers, SaeHeum Song, Indravadan J. Patel, Elliott Marshall Antman, Robert Patrick Giugliano, Satoshi Kunitada, Bruce E. Dornseif et al. · 2012 · Thrombosis and Haemostasis
  58. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial
    Raffaele De Caterina, Giulia Renda, Anthony Carnicelli, Francesco Nordio, Marco Trevisan, Michele F. Mercuri, Christian Thomas Ruff, Elliott Marshall Antman, Eugene Braunwald, Robert Patrick Giugliano · 2017 · Journal of the American College of Cardiology
  59. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH
    Geoffrey D. Barnes, Walter Ageno, Jack Ansell, Scott S. Kaatz · 2015 · Journal of Thrombosis and Haemostasis
  60. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1
    Hans‐Christoph Diener, James Aisenberg, Jack Ansell, Dan Atar, GÜNTER E. BREITHARDT, John W. Eikelboom, Michael D. Ezekowitz, Christopher Bull Granger, Jonathan L. Halperin, Stefan Hans Hohnloser et al. · 2016 · European Heart Journal
  61. Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study
    Giancarlo Agnelli, Cecilia Becattini, Rupert Martin Bauersachs, Benjamin Brenner, Mauro Campanini, Alexander Thomas Cohen, Jean M. Connors, Andrea Fontanella, Gualberto Gussoni, Menno Volkert Huisman et al. · 2018 · Thrombosis and Haemostasis
  62. Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation
    John W. Eikelboom, Daniel J. Quinlan, Jack Hirsh, Stuart J. Connolly, Jeffrey Ian Weitz · 2017 · JAMA Cardiology
  63. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention
    John Hunter Alexander, DANIEL M. WOJDYLA, Amit N. Vora, Laine Elliott Thomas, Christopher Bull Granger, Shaun G. Goodman, RONALD S. ARONSON, Stephan Windecker, Roxana Mehran, Renato D. Lópes · 2020 · Circulation
  64. A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation
    J C Cowan, Jianhua Wu, Marlous Hall, Andi Orlowski, Robert Michael West, Chris P Gale · 2018 · European Heart Journal
  65. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2
    Hans‐Christoph Diener, James Aisenberg, Jack Ansell, Dan Atar, GÜNTER E. BREITHARDT, John W. Eikelboom, Michael D. Ezekowitz, Christopher Bull Granger, Jonathan L. Halperin, Stefan Hans Hohnloser et al. · 2016 · European Heart Journal
  66. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)
    Gregory Y.H. Lip, Jean‐Philippe Collet, Raffaele De Caterina, Laurent Fauchier, Deirdre A. Lane, Torben Bjerregaard Larsen, Francisco R. Marín, João Morais, Calambur Narasimhan, Brian Olshansky et al. · 2017 · EP Europace
  67. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation
    Myung‐Jin Cha, Eue‐Keun Choi, Kyungdo Han, So‐Ryoung Lee, Woo‐Hyun Lim, Seil Oh, Gregory Y.H. Lip · 2017 · Stroke
  68. Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty: The STARS E-3 Trial
    Takeshi Fuji, Ching‐Jen Wang, Satoru Fujita, Yohko Kawai, Mashio Nakamura, Tetsuya Kimura, Kei Ibusuki, Hitoshi Ushida, Kenji Abe, Shintaro Tachibana · 2014 · Thrombosis Research
  69. Association of prothrombin complex concentrate administration and hematoma enlargement in non–vitamin K antagonist oral anticoagulant–related intracerebral hemorrhage
    Stefan T. Gerner, Joji B. Kuramatsu, Jochen A. Sembill, Maximilian I. Sprügel, Matthias Endres, Karl Georg Hæusler, Peter Vajkoczy, Peter Arthur Ringleb, Jan Christoph Purrucker, Timolaos Rizos et al. · 2018 · Annals of Neurology
  70. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
    Margarita Kushnir, Yun Young Choi, Ruth E. Eisenberg, Devika Rao, Seda Serra Tolu, Jackson Y Gao, Wenzhu Bi Mowrey, Henny Heisler Billett · 2019 · The Lancet Haematology
  71. Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance
    Karlyn A. Martin, Craig R. Lee, Timothy Michael Farrell, Stephan Moll · 2017 · The American Journal of Medicine
  72. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis
    Clapton S. Dias, Kenneth Todd Moore, Joe Murphy, Jay Ariyawansa, William Burton Smith, Roger M. Mills, Matthew R. Weir · 2016 · American Journal of Nephrology
  73. Oral anticoagulation in surgical procedures: risks and recommendations
    Marieke Torn, Frits Richard Rosendaal · 2003 · British Journal of Haematology
  74. Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
    Renato D. Lópes, Hwanhee Hong, Ralf E. Harskamp, Deepak L. Bhatt, Roxana Mehran, Christopher Paul Cannon, Christopher Bull Granger, Freek W.A. Verheugt, Jianghao Li, Jurriën M. ten Berg et al. · 2020 · JAMA Cardiology
  75. Non-cardiac surgery in patients with coronary stents: the RECO study
    Pierre Albaladejo, Emmanuel Marret, Charles Marc Samama, Jean‐Philippe Collet, Kou Abhay, Olivier Loutrel, Hélène Charbonneau, Samir Jaber, Sophie Thoret, Jean‐Luc Bosson et al. · 2011 · Heart
  76. Is There an Obesity Paradox for Outcomes in Atrial Fibrillation?
    Marco Proietti, Elisa Guiducci, Paola Cheli, Gregory Y.H. Lip · 2017 · Stroke
  77. Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease
    Giulia Renda, Fabrizio Ricci, Robert Patrick Giugliano, Raffaele De Caterina · 2017 · Journal of the American College of Cardiology
  78. Quality of Care for Atrial Fibrillation Among Patients Hospitalized for Heart Failure
    Jonathan Paul Piccini, Adrian F. Hernandez, Xin Zhao, Manesh R. Patel, William R. Lewis, Eric David Peterson, Gregg C. Fonarow · 2009 · Journal of the American College of Cardiology
  79. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial
    Jean‐Philippe Collet, Sérgio Luis Berti, Angel R. Cequier, Eric VAN BELLE, Thierry Lefèvre, Pascal N. Leprince, Franz‐Josef Neumann, Éric Vicaut, Gilles Montalescot · 2018 · American Heart Journal
  80. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial
    Giuseppe Boriani, Christian Thomas Ruff, Julia Kuder, Minggao Shi, Hans Lanz, Howard Rutman, Michele F. Mercuri, Elliott Marshall Antman, Eugene Braunwald M. D, Robert Patrick Giugliano · 2018 · European Heart Journal
  81. Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery
    Michelle M. Graham, Daniel I. Sessler, Joel L. Parlow, Bruce McClure Biccard, Gordon Henry Guyatt, Kate Leslie, Matthew T.V. Chan, Christian Sylvest Meyhoff, Denis Xavier, Alben Sigamani et al. · 2018 · Annals of Internal Medicine
  82. Incidence and management of seizures after ischemic stroke
    Jeffrey Z. Wang, Manav V. Vyas, Gustavo Saposnik, Jorge G. Burneo · 2017 · Neurology
  83. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF
    Sean T. Chen, Anne S. Hellkamp, Richard Clinton Becker, Scott D. Berkowitz, GÜNTER E. BREITHARDT, Keith A.A. Fox, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Kenneth W. Mahaffey et al. · 2018 · European Heart Journal - Quality of Care and Clinical Outcomes
  84. Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial
    Yutao Guo, Deirdre A. Lane, Yundai Chen, Gregory Y.H. Lip · 2020 · The American Journal of Medicine
  85. A Review of Potential Harmful Interactions between Anticoagulant/Antiplatelet Agents and Chinese Herbal Medicines
    Hsin-Hui Tsai, Hsiang‐Wen Lin, Ying-Hung Lu, Yi‐Ling Chen, Gail B. Mahady · 2013 · PLoS ONE
  86. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial
    Meena P. Rao, Dragoş Vinereanu, DANIEL M. WOJDYLA, John Hunter Alexander, Dan Atar, Elaine M. Hylek, Michael Hanna, Lars C. Wallentin, Renato D. Lópes, Bernard John Gersh et al. · 2017 · The American Journal of Medicine
  87. Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers
    Jeanne Mendell, Masaya Tachibana, Minggao Shi, Satoshi Kunitada · 2010 · The Journal of Clinical Pharmacology
  88. Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage
    Tze‐Fan Chao, Chia‐Jen Liu, Jo‐Nan Liao, Kang-Ling Wang, Yenn‐Jiang Lin, Shih‐Lin Chang, Li‐Wei Lo, Yu‐Feng Hu, Ta‐Chuan Tuan, Fa‐Po Chung et al. · 2016 · Circulation
  89. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies
    Krystin Krauel, Christine Hackbarth, Birgitt Fürll, Andreas Greinacher · 2011 · Blood
  90. Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation
    Tze‐Fan Chao, Kang-Ling Wang, Chia-Jen Liu, Yenn‐Jiang Lin, Shih‐Lin Chang, Li‐Wei Lo, Yu‐Feng Hu, Ta‐Chuan Tuan, Fa‐Po Chung, Jo‐Nan Liao et al. · 2015 · Journal of the American College of Cardiology
  91. Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding
    Wayne A. Ray, Cecilia P. Chung, Katherine T. Murray, Walter E. Smalley, James R. Daugherty, William D. Dupont, C. Michael Stein · 2016 · Gastroenterology
  92. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy
    Renato D. Lópes, Patrícia O. Guimarães, Brad J. Kolls, DANIEL M. WOJDYLA, Cheryl Bushnell, Michael Hanna, J. Donald Easton, Laine Elliott Thomas, Lars C. Wallentin, Sana M. Al‐Khatib et al. · 2017 · Blood
  93. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight
    Stefan Hans Hohnloser, Marat Fudim, John Hunter Alexander, DANIEL M. WOJDYLA, Justin Adrian Ezekowitz, Michael Hanna, Dan Atar, Ziad Hijazi, Maria Cecilia Bahit, Sana M. Al‐Khatib et al. · 2019 · Circulation
  94. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP
    Sung B. Lee, Edward M. Manno, Kennith F. Layton, Eelco F. M. Wijdicks · 2006 · Neurology
  95. Edoxaban in Asian Patients With Atrial Fibrillation
    So‐Ryoung Lee, Eue‐Keun Choi, Kyungdo Han, Jin‐Hyung Jung, Seil Oh, Gregory Y.H. Lip · 2018 · Journal of the American College of Cardiology
  96. Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach
    James Demetrios Douketis · 2011 · Blood
  97. Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation
    Sean van Diepen, Anne S. Hellkamp, Manesh R. Patel, Richard Clinton Becker, GÜNTER E. BREITHARDT, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Christopher C. Nessel, Daniel E. Singer et al. · 2013 · Circulation Heart Failure
  98. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation
    Jean‐Pierre Bassand, Gabriele Accetta, Wael A. Almahmeed, Ramon L. Corbalan, John W. Eikelboom, David Andrew Fitzmaurice, Keith A.A. Fox, Haiyan Gao, Samuel Zachary Goldhaber, Shinya Goto et al. · 2018 · PLoS ONE
  99. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non‐valvular atrial fibrillation: Results from ROCKET AF
    Ihab G. Girgis, Manesh R. Patel, Gary R. Peters, Kenneth Todd Moore, Kenneth W. Mahaffey, Christopher C. Nessel, Jonathan L. Halperin, Robert M. Califf, Keith A.A. Fox, Richard Clinton Becker · 2014 · The Journal of Clinical Pharmacology
  100. Direct Oral Anticoagulants
    Jerrold H. Levy, Alex C. Spyropoulos, Charles Marc Samama, James Demetrios Douketis · 2014 · JACC: Cardiovascular Interventions
  101. Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation
    David Julian Seiffge, Maurizio Paciaroni, Duncan Wilson, Masatoshi Koga, Kosmas Macha, Manuel Cappellari, Sabine A. Schaedelin, Clare Shakeshaft, Masahito Takagi, Georgios K. Tsivgoulis et al. · 2019 · Annals of Neurology
  102. Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation
    Leif Friberg, Tommy Andersson, Mårten Rosenqvist · 2019 · European Heart Journal
  103. Validation of a Modified CHA 2 DS 2 -VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation
    Tze‐Fan Chao, Gregory Y.H. Lip, Chia‐Jen Liu, Ta‐Chuan Tuan, Su‐Jung Chen, Kang-Ling Wang, Yenn‐Jiang Lin, Shih‐Lin Chang, Li‐Wei Lo, Yu‐Feng Hu et al. · 2016 · Stroke
  104. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial
    Tze‐Fan Chao, Shih‐Ann Chen, Christian Thomas Ruff, Rose A. Hamershock, Michele F. Mercuri, Elliott Marshall Antman, Eugene Braunwald, Robert Patrick Giugliano · 2018 · European Heart Journal
  105. Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine
    Dolly A. Parasrampuria, Jeanne Mendell, Minggao Shi, Nobuko Matsushima, Hamim Zahir, Kenneth E. Truitt · 2016 · British Journal of Clinical Pharmacology
  106. Antithrombotic agents and traumatic brain injury in the elderly population: hemorrhage patterns and outcomes
    Pasquale Scotti, Chantal Séguin, Benjamin Lo, Élaine de Guise, Jean-Marc Troquet, Judith Marcoux · 2019 · Journal of neurosurgery
  107. Patient outcomes using the European label for dabigatran
    Andreas Clemens, Herbert Noack, Jorge Ferreira, Stuart J. Connolly, Salim Yusuf, Gregory Y.H. Lip · 2013 · Thrombosis and Haemostasis
  108. eGFR and Albuminuria in Relation to Risk of Incident Atrial Fibrillation: A Meta-Analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study.
    N. Bansal, Leila R. Zelnick, Á. Alonso, E. Benjamin, I. D. de Boer, R. Deo, R. Katz, B. Kestenbaum, Jehu S. Mathew, C. Robinson-Cohen et al. · 2017 · American Society of Nephrology. Clinical Journal
  109. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation
    So‐Ryoung Lee, Eue‐Keun Choi, Soonil Kwon, Kyungdo Han, Jin‐Hyung Jung, Myung‐Jin Cha, Seil Oh, Gregory Y.H. Lip · 2019 · Stroke
  110. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?
    Nikolaos Dagres, Tze‐Fan Chao, Guilherme Fenelon, Luis Aguinaga, Daniel A. Benhayon, Emelia J. Benjamin, Thomas Jared Bunch, Lin Y. Chen, Shih‐Ann Chen, Francisco Darrieux et al. · 2018 · EP Europace
  111. Brandão LR, Albisetti M, Halton J, et al; DIVERSITY Study Investigators. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020;135(7):491-504.
    Leonardo Rodrigues Brandão, Manuela Albisetti, Jacqueline Halton, Lisa R. Bomgaars, Elizabeth A. Chalmers, Lesley Gayle Mitchell, Ildar N. Nurmeev, Pavel Svirin, Tomáš Kuhn, Ondřej Zapletal et al. · 2019 · Blood
  112. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine
    John Hunter Alexander, Ulrika Andersson, Renato D. Lópes, Ziad Hijazi, Stefan Hans Hohnloser, Justin Adrian Ezekowitz, Sigrun Halvorsen, Michael Hanna, Patrick Commerford, Witold Rużyłło et al. · 2016 · JAMA Cardiology
  113. Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs
    Alessandro Galgani, Caterina Palleria, Luigi Francesco Iannone, Giovambattista De Sarro, Filippo Sean Giorgi, Marta C.E. Maschio, Emilio Russo · 2018 · Frontiers in Neurology
  114. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials
    Potpara, Tatjana S, Mujovic, Nebojsa, Proietti, Marco, Dagres, Nikolaos, Hindricks, Gerhard, Collet, Jean-Phillipe, Valgimigli, Marco, Heidbuchel, Hein, Lip, Gregory Y H · 2020 · EP Europace
  115. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V
    Takeshi Fuji, Satoru Fujita, Yohko Kawai, Mashio Nakamura, Tetsuya Kimura, Masayuki Fukuzawa, Kenji Abe, Shintaro Tachibana · 2015 · Thrombosis Journal
  116. Off-label dosing of non–vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation
    Yi‐Hsin Chan, Tze‐Fan Chao, Shao‐Wei Chen, Hsin‐Fu Lee, Yung‐Hsin Yeh, Ya-Chi Huang, Shang‐Hung Chang, Chi-Tai Kuo, Gregory Y.H. Lip, Shih‐Ann Chen · 2020 · Heart Rhythm
  117. Coadministration of Dabigatran Etexilate and Atorvastatin
    Joachim Stangier, Karin Rathgen, Hildegard Stähle, Kathrin Reseski, Thomas Körnicke, Willy Roth · 2009 · American Journal of Cardiovascular Drugs
  118. Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)
    Hakeam A. Hakeam, Nasser A. Al-Sanea · 2017 · Journal of Thrombosis and Thrombolysis
  119. Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke
    Ying Xian, Haolin Xu, Emily Claire O'Brien, Shreyansh D. Shah, Laine Elliott Thomas, Michael J. Pencina, Gregg C. Fonarow, DaiWai M. Olson, Lee H. Schwamm, Deepak L. Bhatt et al. · 2019 · JAMA Neurology
  120. Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight
    So‐Ryoung Lee, Eue‐Keun Choi, Chan Soon Park, Kyungdo Han, Jin‐Hyung Jung, Seil Oh, Gregory Y.H. Lip · 2019 · Journal of the American College of Cardiology
  121. The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
    Jeanne Mendell, Shuquan Chen, Ling He, Madhuri Desai, Dolly A. Parasramupria · 2015 · Clinical Drug Investigation
  122. The pooled incidence of post-stroke seizure in 102 008 patients
    Safeng Zou, Xiaomei Wu, Bo Zhu, Jinyang Yu, Bowen Yang, Jingpu Shi · 2015 · Topics in Stroke Rehabilitation
  123. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE)
    Raquel Barba, Javier Marco, Helena Martín-Alvarez, P. Rondón, Carmen Fernández‐Capitán, Ferrán García-Bragado, Manuel Monréal · 2005 · Journal of Thrombosis and Haemostasis
  124. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage
    Jennifer Ann Frontera, Prachi Bhatt, Rebecca Lalchan, Shadi R. Yaghi, Tania Ahuja, John Papadopoulos, Danielle Joset · 2019 · Journal of Thrombosis and Thrombolysis
  125. Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation
    Hee Tae Yu, Pil‐Sung Yang, Eunsun Jang, Tae‐Hoon Kim, Jae‐Sun Uhm, Jong‐Youn Kim, Hui‐Nam Pak, Moon‐Hyoung Lee, Gregory Y.H. Lip, Boyoung Joung · 2020 · Journal of the American Heart Association
  126. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?
    Nikolaos Dagres, Tze‐Fan Chao, Guilherme Fenelon, Luis Aguinaga, Daniel A. Benhayon, Emelia J. Benjamin, Thomas Jared Bunch, Lin Y. Chen, Shih‐Ann Chen, Francisco Darrieux et al. · 2018 · Journal of Arrhythmia
  127. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
    Jonas Oldgren, Philippe Gabríel Steg, Stefan Hans Hohnloser, Gregory Y.H. Lip, Takeshi Kimura, Matias Nordaby, Martina Brueckmann, Eva Kleine, Jurriën M. ten Berg, Deepak L. Bhatt et al. · 2019 · European Heart Journal
  128. Effects of dabigatran according to age in atrial fibrillation
    Mandy N. Lauw, John W. Eikelboom, Michiel Coppens, Lars C. Wallentin, Salim Yusuf, Michael D. Ezekowitz, Jonas Oldgren, Juliet Nakamya, Jia Wang, Stuart J. Connolly · 2017 · Heart
  129. Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding
    Yan Xu, Sam Schulman, Dar D Dowlatshahi, Anne Marie Holbrook, Christopher S. Simpson, Lois E. Shepherd, Philip Stephen Wells, Antonio Giulivi, Tara Gomes, Muhammad Mamdani et al. · 2017 · CHEST Journal
  130. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial)
    Somasekhara R. Balla, Derek D. Cyr, Yuliya V. Lokhnygina, Richard Clinton Becker, Scott D. Berkowitz, GÜNTER E. BREITHARDT, Keith A.A. Fox, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey et al. · 2017 · The American Journal of Cardiology
  131. Comparison of initial warfarin response in obese patients versus non-obese patients
    Jessica L. Wallace, Anne B. Reaves, Elizabeth A. Tolley, Carrie S. Oliphant, Lydia Hutchison, Numan Alabdan, Christopher W. Sands, Timothy H. Self · 2012 · Journal of Thrombosis and Thrombolysis
  132. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population‐based cohort study
    Anne Gulbech Ording, Erzsébet Horváth–Puhó, Kasper Adelborg, Lars Henning Pedersen, Paolo Prandoni, Henrik Toft Sørensen · 2017 · Cancer Medicine
  133. Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation
    Malini Madhavan, DaJuanicia N. Holmes, Jonathan Paul Piccini, Jack Ansell, Gregg C. Fonarow, Elaine M. Hylek, Peter Russell Kowey, Kenneth W. Mahaffey, Laine Elliott Thomas, Eric David Peterson et al. · 2019 · American Heart Journal
  134. Warfarin versus direct oral anticoagulants for treating left ventricular thrombus: a systematic review and meta-analysis
    Tarun Dalia, Shubham Lahan, Sagar Ranka, Amandeep Goyal, Sara Zoubek, Kamal Gupta, Zubair I. Shah · 2021 · Thrombosis Journal
  135. Racial/Ethnic Differences in Ischemic Stroke Rates and the Efficacy of Warfarin Among Patients With Atrial Fibrillation
    Albert Yuh‐Jer Shen, Janis F. Yao, Somjot Singh Brar, Michael B. Jorgensen, Xunzhang Wang, Wansu Chen · 2008 · Stroke
  136. Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin
    Ryota Kurogi, Kunihiro Nishimura, Michikazu Nakai, Akiko Kada, Satoru Kamitani, Jyoji Nakagawara, Ḱazunori Toyoda, Kuniaki Ogasawara, Junichi Ono, Yoshiaki Shiokawa et al. · 2018 · Neurology
  137. Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials
    Subodh Verma, Shaun G. Goodman, Shamir R. Mehta, David A. Latter, Marc Ruel, Milan Gupta, Bobby Yanagawa, Mohammed A. Al-Omran, Nandini Gupta, Hwee Teoh et al. · 2015 · BMC Surgery
  138. Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation
    Jean‐Pierre Bassand, Saverio Virdone, Samuel Zachary Goldhaber, A. John Camm, David Andrew Fitzmaurice, Keith A.A. Fox, Shinya Goto, Sylvia K. Haas, Werner Hacke, Gloria Kayani et al. · 2019 · Circulation
  139. Evolving Changes of the Use of Oral Anticoagulants and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation in Taiwan
    Tze‐Fan Chao, Chern‐En Chiang, Yenn‐Jiang Lin, Shih‐Lin Chang, Li‐Wei Lo, Yu‐Feng Hu, Ta‐Chuan Tuan, Jo‐Nan Liao, Fa‐Po Chung, Tzeng‐Ji Chen et al. · 2018 · Circulation
  140. Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran
    Joanne van Ryn, Lawrence Baruch, Andreas Clemens · 2012 · The American Journal of Medicine
  141. Efficacy and Safety of Edoxaban Compared with Warfarin in Patients with Atrial Fibrillation and Heart Failure: Insights from ENGAGE AF-TIMI 48
    Giulia Magnani, Robert Patrick Giugliano, Christian Thomas Ruff, Sabina A. Murphy, Francesco Nordio, Marco Metra, Tiziano Moccetti, Veselin L. Mitrović, Minggao Shi, Michele F. Mercuri et al. · 2016 · European Journal of Heart Failure
  142. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis
    Ying Bai, Shi-Dong Guo, Hai Deng, Alena Shantsila, Laurent Fauchier, Changsheng Ma, Gregory Y.H. Lip · 2017 · Age and Ageing
  143. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation
    Kazuhiko Kido, Surachat Ngorsuraches · 2018 · Annals of Pharmacotherapy
  144. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR
    Hideyuki Kawashima, Yusuke Watanabe, Hirofumi Hioki, Ken Kozuma, Akihisa Kataoka, Makoto Nakashima, Fukuko Nagura, Yugo Nara, Fumiaki Yashima, Norio Tada et al. · 2020 · JACC: Cardiovascular Interventions
  145. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial
    Jan Steffel, Robert Patrick Giugliano, Eugene Braunwald, Sabina A. Murphy, Dan Atar, Hein Heidbüchel, A. John Camm, Elliott Marshall Antman, Christian Thomas Ruff · 2015 · European Heart Journal
  146. Compared to warfarin, direct oral anticoagulants are associated with lower mortality in patients with blunt traumatic intracranial hemorrhage
    James M. Feeney, Elizabeth Santone, Monica M. DiFiori, Lilla Kis, Vijay M. Jayaraman, Stephanie C. Montgomery · 2016 · The Journal of Trauma: Injury, Infection, and Critical Care
  147. Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants
    Chan Soon Park, Eue‐Keun Choi, Hyue Mee Kim, So‐Ryoung Lee, Myung‐Jin Cha, Seil Oh · 2016 · Heart Rhythm
  148. Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119)
    Luise Tittl, Sebastian Endig, S. Marten, Antje Reitter, Ines Beyer-Westendorf, Jan Beyer‐Westendorf · 2018 · International Journal of Cardiology
  149. Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine
    Justin D. Lutz, Brian J. Kirby, Lu Wang, Qinghua Song, John R. Ling, Benedetta Massetto, Angela Worth, Brian P. Kearney, Anita A. Mathias · 2018 · Clinical Pharmacology & Therapeutics
  150. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease
    Joseph H. Schafer, Ashley L. Casey, Kristina A. Dupre, Britta A. Staubes · 2018 · Annals of Pharmacotherapy
  151. Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation
    So‐Ryoung Lee, Young Soo Lee, Ji-Suck Park, Myung‐Jin Cha, Tae‐Hoon Kim, Junbeom Park, Jin‐Kyu Park, Jung‐Myung Lee, Ki‐Woon Kang, Jaemin Shim et al. · 2019 · Yonsei Medical Journal
  152. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention
    Stephan Windecker, Renato D. Lópes, Tyler Massaro, Charlotte Jones-Burton, Christopher Bull Granger, RONALD S. ARONSON, Gretchen Heizer, Shaun G. Goodman, Harald Darius, W. Schuyler Jones et al. · 2019 · Circulation
  153. Left atrial catheter ablation and ischemic stroke
    Haeusler, Karl Georg, Kirchhof, Paulus, Endres, Matthias · 2012 · Stroke
  154. Oral anticoagulant and reduced risk of dementia in patients with atrial fibrillation: A population-based cohort study
    Pajaree Mongkhon, Laura Fanning, Wallis C. Y. Lau, Gary Tse, Kui Kai Lau, Li Wei, Chuenjid Kongkaew, Ian Chi Kei Wong · 2020 · Heart Rhythm
  155. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures
    Armando Tripodi · 2016 · Journal of Thrombosis and Haemostasis
  156. The effect of bariatric surgery on direct-acting oral anticoagulant drug levels
    Amihai Rottenstreich, Aviv Barkai, Ariela Arad, Bruria Hirsh Raccah, Yosef Kalish · 2017 · Thrombosis Research
  157. Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non–Vitamin K Antagonist Oral Anticoagulants
    Tomas Forslund, Joris J. Komen, Morten Tolstrup Andersen, Björn Wettermark, Mia von Euler, Aukje Kaija Mantel-Teeuwisse, Frieder Braunschweig, Paul Hjemdahl · 2018 · Stroke
  158. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants
    Andres A. Enriquez, Gregory Y.H. Lip, Adrian M Baranchuk · 2015 · EP Europace
  159. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial
    Robert Patrick Giugliano, Christian Thomas Ruff, Stephen D. Wiviott, Francesco Nordio, Sabina A. Murphy, Johannes A.N. Kappelhof, Minggao Shi, Michele F. Mercuri, Elliott Marshall Antman, Eugene Braunwald · 2016 · The American Journal of Medicine
  160. Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial
    Nicolas M. Van Mieghem, Martin Unverdorben, Marco Valgimigli, Roxana Mehran, Eric H. Boersma, Usman Baber, Christian Hengstenberg, Minggao Shi, Cathy Yi-Hsuan Chen, Shigeru Saito et al. · 2018 · American Heart Journal
  161. Incidence of seizures following initial ischemic stroke in a community-based cohort: The Framingham Heart Study
    Maria Stefanidou, Rohit R Das, Alexa Beiser, Banu Sundar, Margaret Kelly‐Hayes, Carlos S. Kase, Orrin Devinsky, Sudha S. Seshadri, Daniel J. Friedman · 2017 · Seizure
  162. Increased rates of atrial fibrillation recurrence following pulmonary vein isolation in overweight and obese patients
    Bhradeev Sivasambu, Muhammad Adnan Balouch, Tarek Zghaib, Rizma Jalees Bajwa, Jonathan Chrispin, Ronald David Berger, Hiroshi Ashikaga, Saman Nazarian, Joseph Edward Marine, Hugh G Calkins et al. · 2017 · Journal of Cardiovascular Electrophysiology
  163. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy
    Hyunjean Jung, Pil‐Sung Yang, Eunsun Jang, Hee Tae Yu, Tae‐Hoon Kim, Jae‐Sun Uhm, Jong‐Youn Kim, Hui‐Nam Pak, Moon‐Hyoung Lee, Boyoung Joung et al. · 2018 · CHEST Journal
  164. Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure
    Joseph R. Shaw, Na Li, Thomas Vanassche, Michiel Coppens, Alex C. Spyropoulos, Summer Syed, Mansoor Radwi, Joanne M. Duncan, Sam Schulman, James Demetrios Douketis · 2020 · Blood Advances
  165. Rivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin‐induced thrombocytopenia
    Jeanine M. Walenga, Margaret Prechel, Walter P Jeske, Debra Hoppensteadt, Jyothi Maddineni, Omer Iqbal, Harry L. Messmore, Mamdouh Bakhos · 2008 · British Journal of Haematology
  166. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism
    Jan Steffel, Eugene Braunwald · 2011 · European Heart Journal
  167. Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests
    Favresse, Julien, Lardinois, Benjamin, Sabor, Lina, Devalet, Bérangère, Vandepapeliere, Julie, Braibant, Maximilien, Lessire, Sarah, Chatelain, Bernard, Jacqmin, Hugues, Douxfils, Jonathan et al. · 2018 · TH Open
  168. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation
    Adrian Matthew Shields, Gregory Y.H. Lip · 2015 · Journal of Internal Medicine
  169. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people
    Olivier Hanon, Patrick Assayag, Joël Belmin, Jean‐Philippe Collet, J.P. Émeriau, Laurent Fauchier, Françoise Forette, Patrick Friocourt, Armelle Gentric, Christophe Leclercq et al. · 2013 · Archives of cardiovascular diseases
  170. Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment
    Yukihiro Koretsune, Takeshi Yamashita, Tetsuya Kimura, Masayuki Fukuzawa, Kenji Abe, Masahiro Yasaka · 2015 · Circulation Journal
  171. Cerebral Ischemia in Patients on Direct Oral Anticoagulants
    Kosmas Macha, Armin Marsch, Gabriela Siedler, Lorenz Breuer, Erwin F. Strasser, Tobias Engelhorn, Stefan Schwab, Bernd Kallmünzer · 2019 · Stroke
  172. Antithrombotic Effects of Naturally Derived Products on Coagulation and Platelet Function
    Shaker A. Mousa · 2010 · Methods in molecular biology
  173. Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism
    Wonkyung Byon, Kevin Sweeney, C Frost, RA Boyd · 2017 · CPT Pharmacometrics & Systems Pharmacology
  174. Frailty syndrome: an emerging clinical problem in the everyday management of clinical arrhythmias. The results of the European Heart Rhythm Association survey
    Stefano Fumagalli, Tatjana Potpara, Torben Bjerregaard Larsen, Kristina Hermann Haugaa, Dan Dobreanu, Alessandro Proclemer, Nikolaos Dagres · 2017 · EP Europace
  175. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs
    Claudia Stöllberger, Josef Finsterer · 2016 · Epilepsy Research
  176. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study
    Gary E. Raskob, Walter Ageno, Alexander Thomas Cohen, Marjolein P. A. Brekelmans, MICHAEL A. GROSSO, Annelise E.M. Segers, Guy Meyer, Peter B. Verhamme, Philip Stephen Wells, Min Lin et al. · 2016 · The Lancet Haematology
  177. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016
    Géric Maura, Cécile Billionnet, Jérôme Drouin, Alain Weill, Anke Neumann, Antoine Pariente · 2019 · BMJ Open
  178. How Long After Drug Ingestion Is Activated Charcoal Still Effective?
    Robert S. Green, Robert Grierson, DANIEL S. SITAR, Milton Tenenbein · 2001 · Journal of Toxicology Clinical Toxicology
  179. Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants
    Pierre Albaladejo, Charles Marc Samama, Piérre Siè, Sophie Kauffmann, Vincent Mémier, Pierre Suchon, Alain Viallon, Jean David, Yves Gruel, Lorenn Bellamy et al. · 2017 · Anesthesiology
  180. Prevalence and Resolution of Left Atrial Thrombus in Patients With Nonvalvular Atrial Fibrillation and Flutter With Oral Anticoagulation
    Adam Niku, Takahiro Shiota, Robert James Siegel, Florian Rader · 2018 · The American Journal of Cardiology
  181. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease
    Matthew R. Weir, Veronica Ashton, Kenneth Todd Moore, Shubham Shrivastava, Eric David Peterson, Eric M. Ammann · 2020 · American Heart Journal
  182. Vitamin K Antagonists Predispose to Calciphylaxis in Patients with End-Stage Renal Disease
    Peter A. Galloway, Ragada El-Damanawi, Victoria Bardsley, N.R. Pritchard, Andrew C. Fry, Sanjay Kumar Ojha, Thomas F. Hiemstra · 2015 · The Nephron journals/Nephron journals
  183. Direct oral anticoagulant use in left ventricular thrombus
    Zafar Ali, Nicholas Isom, Tarun Dalia, Farhad A. Sami, Uzair A. Mahmood, Zubair I. Shah, Kamal Gupta · 2020 · Thrombosis Journal
  184. Comparison of Safety of Left Atrial Catheter Ablation Procedures for Atrial Arrhythmias Under Continuous Anticoagulation With Apixaban Versus Phenprocoumon
    Bernhard M. Kaess, Sonia Ammar, Tilko Reents, Roger Dillier, Carsten Lennerz, Verena Semmler, Christian Grebmer, Felix J. Bourier, Alessandra Buiatti, Christof Kolb et al. · 2014 · The American Journal of Cardiology
  185. Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta‐Analysis
    Yuqing Deng, Yifan Tong, Yuanyuan Deng, Le Zou, Shunhui Li, Hui Chen · 2019 · Journal of the American Heart Association
  186. Apixaban versus enoxaparin in patients with total knee arthroplasty
    Jiahao Huang, Cun Liao, Liucheng Wu, Yunfei Cao, Feng Gao · 2010 · Thrombosis and Haemostasis
  187. Reversal of apixaban anticoagulation by four‐factor prothrombin complex concentrates in healthy subjects: a randomized three‐period crossover study
    Y. Song, Zhaoqing Wang, Itay Perlstein, J. Wang, Frank P. LaCreta, Robert J. Frost, C. Frost · 2017 · Journal of Thrombosis and Haemostasis
  188. Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage
    So‐Ryoung Lee, Eue‐Keun Choi, Soonil Kwon, Jin‐Hyung Jung, Kyungdo Han, Myung‐Jin Cha, Seil Oh, Gregory Y.H. Lip · 2019 · Stroke
  189. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation
    Sachin J. Shah, Daniel E. Singer, Margaret C. Fang, Kristi Reynolds, Alan S. Go, Mark H. Eckman · 2019 · Circulation Cardiovascular Quality and Outcomes
  190. Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban
    Kenneth Todd Moore, Alexei N. Plotnikov, An Thyssen, Nicole M. Vaccaro, Jay Ariyawansa, Paul B.J. Burton · 2011 · Journal of Cardiovascular Pharmacology
  191. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban
    Charles E. Frost, Andrew Shenker, Mohit D. Gandhi, Janice M. Pursley, Yu Chen Barrett, Jessie J.J. Wang, Donglu Zhang, Wonkyung Byon, Rebecca A. Boyd, Frank P. LaCreta · 2014 · British Journal of Clinical Pharmacology
  192. Atrial Fibrillation Patients Treated With Long‐Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long‐Term Warfarin for Other Indications
    Thomas Jared Bunch, Heidi Thomas May, Tami L. Bair, Brian G. Crandall, Michael J. Cutler, John D. Day, Victoria Jacobs, Charles D. Mallender, Jeffrey S. Osborn, Scott M. Stevens et al. · 2016 · Journal of the American Heart Association
  193. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF
    Sylvia K. Haas, A. John Camm, Jean‐Pierre Bassand, Pantep Angchaisuksiri, Frank J.S. Cools, Ramon L. Corbalan, Harry H. Gibbs, Barry Frank Jacobson, Yukihiro Koretsune, Lorenzo Giovanni Mantovani et al. · 2019 · American Heart Journal
  194. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study
    Joris R. de Groot, Thomas Werner Weiss, Peter J. Kelly, Pedro F. Monteiro, Jean‐Claude Deharo, Carlo de Asmundis, Esteban López de Sá, Johannes L. Waltenberger, Jan Steffel, Pierre Lévy et al. · 2020 · European Heart Journal - Cardiovascular Pharmacotherapy
  195. Monitoring and reversal of direct oral anticoagulants
    Adam C. Cuker, Deborah M. Siegal · 2015 · Hematology
  196. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future
    Tomas Salmonson, Jean‐Michel Dogné, Heidi Janssen, Juan García Burgos, Paul Blake · 2016 · European Heart Journal - Cardiovascular Pharmacotherapy
  197. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation
    Fernándo Domínguez, Vicente E Climent, Esther Zorio, Tomás Ripoll‐Vera, Joel Salazar‐Mendiguchía, José Manuel García‐Pinilla, José Ángel Urbano-Moral, Xusto Fernández, David López-Cuenca, Raquel Ajo et al. · 2017 · International Journal of Cardiology
  198. Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation
    Jan Steffel, Christian Thomas Ruff, Ophelia Q. P. Yin, Eugene Braunwald, Jeong‐Gun Park, Sabina A. Murphy, Stuart J. Connolly, Elliott Marshall Antman, Robert Patrick Giugliano · 2021 · Journal of the American College of Cardiology
  199. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight—a systematic literature review
    Raffaele De Caterina, Gregory Y.H. Lip · 2017 · Clinical Research in Cardiology
  200. Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran
    Parag Kumar, Lori A. Gordon, Kristina M. Brooks, Jomy M. George, Anela Kellogg, Maryellen McManus, Raul M. Alfaro, Khanh Nghiem, Jay Nelson Lozier, Colleen M. Hadigan et al. · 2017 · Antimicrobial Agents and Chemotherapy